稳心颗粒联合缬沙坦胶囊治疗阵发性心房颤动临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.7+5

基金项目:


Clinical Study on Wenxin Granules Combined with Valsartan Capsules for Paroxysmal Atrial Fibrillation
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察稳心颗粒联合缬沙坦胶囊治疗阵发性心房颤动的疗效及对心功能、超敏C-反应蛋白(hs-CRP) 水平的影响。方法:回顾性选取82 例阵发性心房颤动患者,根据治疗方式不同分为对照组和观察组各41 例。对照组给予缬沙坦胶囊口服,观察组在对照组基础上加用稳心颗粒治疗。比较2 组临床疗效和治疗前后中医证候评分、房颤发作次数、房颤持续时间、静息心率、心功能、hs-CRP,观察不良反应发生情况。结果:观察组总有效率为92.68%,高于对照组75.61%,差异有统计学意义(P<0.05)。治疗后,2 组心悸、胸闷、气短、神倦乏力、出汗、舌红苔浊腻等中医证候评分较治疗前降低,且观察组各项评分均低于对照组(P<0.05)。治疗后,2 组房颤发作次数、房颤持续时间、静息心率较治疗前降低,且观察组各项指标均低于对照组(P<0.05)。治疗后,2 组左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、P 波离散度(Pd) 较治疗前降低,左室射血分数(LVEF) 较治疗前升高(P<0.05),且观察组LVESD、LVEDD、Pd 低于对照组,LVEF 高于对照组(P<0.05)。治疗后,2 组hs-CRP、N-末端脑钠肽前体(NT-proBNP) 水平较治疗前降低,且观察组hs-CRP、NT-proBNP 水平均低于对照组(P<0.05)。观察组不良反应发生率为4.88%,低于对照组19.51%,差异有统计学意义(P<0.05)。结论:稳心颗粒联合缬沙坦胶囊治疗阵发性心房颤动疗效显著,可改善患者临床症状,降低hs-CRP 水平,控制心率和发作次数,缩短心律失常持续时间,改善心功能,不良反应小。

    Abstract:

    Abstract:Objective:To observe the curative effect of Wenxin granules combined with valsartan capsules for paroxysmal atrial fibrillation and its effect on heart function and levels of high-sensitivity C-reactive protein(hs-CRP). Methods:A total of 82 cases of patients with paroxysmal atrial fibrillation were retrospectively selected and divided into the control group and the observation group according to different treatment methods,with 41 cases in each group. The control group was given oral administration of valsartan capsules,and the observation group was additionally treated with Wenxin granules based on the treatment of the control group. The Chinese medicine syndrome scores, onset frequency and duration of atrial fibrillation, resting heart rate, heart function and hs- CRP before and after treatment and the clinical effects in the two groups were compared. The incidence of adverse reactions was observed. Results:The total effective rate was 92.68% in the observation group,higher than that of 75.61% in the control group,the difference being significant(P<0.05). After treatment,Chinese medicine syndrome scores of palpitation,chest discomfort,shortness of breath,tiredness and weakness,sweating,and red tongue and greasy coating in the two groups were decreased when compared with those before treatment, and the above scores in the observation group were lower than those in the control group(P<0.05). After treatment,onset frequency and duration of atrial fibrillation and resting heart rates in the two groups were decreased when compared with those before treatment, and the above indexes in the observation group were lower than those in the control group(P<0.05). After treatment, left ventricular end systolic dimension(LVESD), left ventricular end diastolic diameter(LVEDD) and P- wave dispersion(Pd) in the two groups were decreased when compared with those before treatment,and left ventricular ejection fraction(LVEF) was increased(P<0.05);LVESD,LVEDD and Pd in the observation group were lower than those in the control group,and LVEF was higher(P<0.05). After treatment,the levels of hs-CRP and N-terminal pro b-type natriuretic peptide (NT-proBNP) in the two groups were decreased when compared with those before treatment,and the levels of hs-CRP and NT-proBNP in the observation group were lower than those in the control group(P<0.05). The incidence of adverse reactions was 4.88% in the observation group, lower than that of 19.51% in the control group, the difference being significant(P< 0.05). Conclusion:Wenxin granules combined with valsartan capsules has a significant curative effect in treating paroxysmal atrial fibrillation,which can improve clinical symptoms and heart function,reduce hs- CRP levels,control heart rates and onset frequency,and shorten duration of arrhythmia,with few adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

李国伟,罗森堡,朱玉强.稳心颗粒联合缬沙坦胶囊治疗阵发性心房颤动临床研究[J].新中医,2022,54(5):78-82

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-03-10
  • 出版日期: